ACADIA Pharmaceuticals Inc.
$25.38
The Read: ACAD’s stock has historically declined sharply on regulatory setbacks like the EMA’s negative CHMP opinion on trofinetide and delayed Phase 3 data releases, while modest revenue growth and product launches have only tempered losses without sparking rallies.
Price
Overlays
Panel
ACAD
Hover to view data
No Data